7
Goossens, M.E., Buntinx, F., Joniau, S., Ackaert, K., Ameye, F., Billiet, I., Braeckman, J., Breugelmans, A., Darras, J., Dilen, K., Goeman, L., Kellen, E., Tombal, B., van Bruwaene, S., van Cleyenbreuge, B., van der Aa, F., Vekemans, K., van Poppel, H., Zeegers, M.P.
Veröffentlicht in: Goossens , M E , Buntinx , F , Joniau , S , Ackaert , K , Ameye , F , Billiet , I , Braeckman , J , Breugelmans , A , Darras , J , Dilen , K , Goeman , L , Kellen , E , Tombal , B , van Bruwaene , S , van Cleyenbreuge , B , van der Aa , F , Vekemans , K , van Poppel , H & Zeegers , M P 2012 , ' Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium ' , BMC Urology , vol. 12 , no. 1 , 8 , pp. 8 . https://doi.org/10.1186/1471-2490-12-8;
2012